Zymeworks Up 10% On Positive Study Results Of Zanidatamab In Biliary Tract Cancer Treatment

On:

Shares of Zymeworks Inc. (ZYME) are rising more than 10% Monday morning after reporting positive topline results from the Phase 2b study of zanidatamab in patients with biliary tract cancers.

Topline results from the Phase 2b HERIZON-BTC-01 study showed that 41.3% of enrolled patients with HER2-amplified and expressing disease achieved an objective response after treatment with zanidatamab.

Full results from the study are expected to be presented in 2023.

ZYME is at $7.17 currently. It has traded in the range of $4.11-$17.27 in the last 1 year.

Source: Read Full Article

Lates News:
  1. Bitcoin Miners Dump $55 Million Worth of $BTC Amid Price Drop to Key Support Level
  2. Cryptos Subdued Ahead Of PCE Data
  3. Analyst Predicts 90% Likelihood of SEC Approving Bitcoin Spot ETF by January 2024 or Earlier
  4. Former Goldman Sachs Exec on Ethereum: ‘This Is the Fastest Growing Economy on Earth’
  5. WISeKey Soars On Plans To Launch New WISeSat-Ready FOSSA Powered Satellites With SpaceX